AMINO ACID SYNTHETIC FORMULA SUPPLEMENTED WITH LONG CHAIN POLYUNSATURATED FATTY ACIDS, MEDIUM CHAIN TRIGLYCERIDES AND 2- FUCOSYLLACTOSE AND LACTO-N-NEOTETRAOSE

Information current as at: 1 June 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Alfamino®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: NESTLE AUSTRALIA LTD
Condition/indication: (therapeutic use): Cows' milk protein enteropathy;

Severe cows' milk protein enteropathy with failure to thrive;

Combined intolerance to cows' milk protein, soy protein and protein hydrolysate formulae;

Cows' milk anaphylaxis;

Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein and soy protein;

Severe intestinal malabsorption including short bowel syndrome;

Eosinophilic oesophagitis.
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New PBS listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: November 2022 PBAC meeting
Opportunity for consumer comment:: Open 27/07/2022 and close 21/09/2022 (see PBS Website)
PBAC meeting:: Held on 02/11/2022
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: 13/01/2023
Lodgement of required documentation:: 16/02/2023
Acceptance of complete documentation:: Accepted
Agreement to listing arrangements:: Commenced on 02/06/2023
Status:: Finalised
Government processes:: Commenced on 18/07/2023
Medicine listed on the PBS:: 01/09/2023 (see PBS schedule)

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

Case ID

a578

Page last updated

31 March 2026

v.9.19